BofA Makes Major Call on Eli Lilly Stock
Bank of America raised its price target for Eli Lilly (LLY) to $1,497 from $1,397, citing stronger-than-expected Q3 results and raised 2026 revenue outlook. LLY reported $24.4B revenue and $7.48 EPS, beating estimates. BofA increased revenue and EPS forecasts, noting strong demand for obesity and diabetes drugs.
How this was made
The 30-second read
Why it matters
The analyst upgrade adds fresh bullish sentiment, likely supporting further price appreciation.
Market read
The target raise provides a new catalyst for LLY, potentially influencing healthcare sector momentum.
What to watch
Potential regulatory scrutiny on obesity drugs or pricing pressures could limit upside.
Background
Eli Lilly reported Q3 2026 revenue of $24.4 bn and non‑GAAP EPS of $7.48, beating estimates and prompting BofA to lift its forecasts.
Ticker impact
Bank of America raised its price target on Eli Lilly to $1,497 from $1,397 after the drugmaker posted stronger‑than‑expected Q3 results.
likely upward pressure as investors price in higher earnings expectations
Analyst target upgrades historically precede short‑term price gains, especially after a beat on revenue and EPS.
Market effects
Strengthens the broader pharma/biotech sector outlook, especially obesity‑drug peers.
Positive for U.S. large‑cap healthcare stocks.
Reinforces global demand trends for obesity and diabetes treatments.
Counterpoint
If the price target increase is already priced in, the stock may face short‑term profit‑taking.
Key entities
- companyEli Lilly
Pharmaceutical company receiving the target raise.
- analystBank of America
Raised LLY price target based on earnings beat.
